Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total value of $108,860.97. Following the transaction, the director now owns 7,177,116 shares in the company, valued at approximately $68,254,373.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 11th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.45, for a total value of $96,727.15.
• On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.17, for a total value of $104,968.99.
• On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.95, for a total value of $91,003.65.
• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.82, for a total value of $100,962.54.

Recursion Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ RXRX opened at $7.50 on Friday. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.97 and a twelve month high of $16.75. The stock has a fifty day simple moving average of $8.84 and a 200-day simple moving average of $9.92. The stock has a market capitalization of $1.78 billion, a PE ratio of -4.69 and a beta of 0.86.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $11.10 million. During the same period in the previous year, the firm posted ($0.34) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on RXRX shares. KeyCorp lifted their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mubadala Investment Co PJSC acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth $128,041,000. Citigroup Inc. boosted its position in shares of Recursion Pharmaceuticals by 165.3% during the 3rd quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock worth $3,599,000 after acquiring an additional 293,174 shares in the last quarter. Gladstone Institutional Advisory LLC acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $133,000. Norges Bank acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $34,825,000. Finally, UBS Group AG boosted its position in shares of Recursion Pharmaceuticals by 103.1% during the 3rd quarter. UBS Group AG now owns 342,679 shares of the company’s stock worth $2,621,000 after acquiring an additional 173,954 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.